IWP
AKBA icon

Icon Wealth Partners’s Akebia Therapeutics AKBA Stock Holding History

Icon Wealth Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50,000
Closed -$28K – 410
2023
Q1 		$28K Buy
+50,000
New +$38.2K ﹤0.01% 419
2022
Q2 		$141K Buy
+400,132
New +$168K 0.02% 293

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Icon Wealth Partners's AKBA Position: Q2 2023 in Review

Icon Wealth Partners sold out of Akebia Therapeutics (AKBA) in Q2 2023, closing a stake of 50,000 shares — an estimated $28K sold.

Icon Wealth Partners first reported a position in AKBA in Q2 2022 and held it in 2 quarters. The position peaked at $141K in Q2 2022. 79 funds tracked by Wall St. Rank hold AKBA as of Q2 2023.

  • Icon Wealth Partners reported no remaining Akebia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Icon Wealth Partners sold 50,000 Akebia Therapeutics shares in Q2 2023, an estimated $28K.
  • Icon Wealth Partners first reported a position in Akebia Therapeutics in Q2 2022 and held it in 2 quarters.
  • Icon Wealth Partners's Akebia Therapeutics position peaked at $141K in Q2 2022.
  • 79 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2023.

Based on Icon Wealth Partners's 13F filing for Q2 2023, filed 3 Aug 2023.